Fusion Pharmaceuticals Inc (FUSN)
21.57
+0.05
(+0.23%)
USD |
NASDAQ |
Jun 03, 16:00
21.57
0.00 (0.00%)
After-Hours: 20:00
Fusion Pharmaceuticals Cash from Operations (TTM): -83.67M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -83.67M |
December 31, 2023 | -81.80M |
September 30, 2023 | -83.22M |
June 30, 2023 | -86.01M |
March 31, 2023 | -83.74M |
December 31, 2022 | -73.28M |
September 30, 2022 | -70.24M |
June 30, 2022 | -70.12M |
March 31, 2022 | -70.12M |
Date | Value |
---|---|
December 31, 2021 | -75.74M |
September 30, 2021 | -62.50M |
June 30, 2021 | -53.85M |
March 31, 2021 | -42.74M |
December 31, 2020 | -29.77M |
September 30, 2020 | -30.52M |
June 30, 2020 | -20.68M |
March 31, 2020 | -18.48M |
December 31, 2019 | -13.69M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-86.01M
Minimum
Jun 2023
-13.69M
Maximum
Dec 2019
-58.34M
Average
-70.12M
Median
Cash from Operations (TTM) Benchmarks
AstraZeneca PLC | 9.698B |
Landos Biopharma Inc (DELISTED) | -20.80M |
Acasti Pharma Inc | -13.57M |
Aurinia Pharmaceuticals Inc | -33.46M |
Edesa Biotech Inc | -6.340M |